Clinical management of gastrointestinal stromal tumors;Traitement des tumeurs stromales digestives

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 10 I, 2004, Pages 893-901

  Landi, Bruno ^a   Lecomte, Thierry ^a   Berger, Anne ^a   Cellier, Christophe ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ARTHRALGIA; ASTHENIA; CANCER ADJUVANT THERAPY; CARCINOMATOUS PERITONITIS; CHEMOEMBOLIZATION; CYTOPENIA; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DOSE RESPONSE; DRUG EFFICACY; DYSPEPSIA; EDEMA; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HEPATIC ARTERIAL CHEMOEMBOLIZATION; HUMAN; HYPERURICEMIA; LIVER METASTASIS; LIVER TOXICITY; METASTASIS; MOLECULAR BIOLOGY; MUSCLE CRAMP; MYELOID LEUKEMIA; NEUTROPENIA; PROGNOSIS; RASH; REVIEW; TUMOR LOCALIZATION; VOMITING;

EID: 7044270610     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(04)95154-8     Document Type: Review

References (68)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
2. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000;15:1293-301.
3. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001;32:578-82.
4. Kindblom LG, Meis-Kindblom J, Bümming P, et al. Incidence, prevalence, phenotype, and biologic spectrum of gastrointestinal stromal tumors: a population based study of 600 cases (abstract). Ann Oncol 2002;13:577.
5. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
6. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
7. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-72.
8. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65.
9. Balaton AJ, Coindre JM, Cvitkovic F. Tumeurs stromales digestives. Gastroenterol Clin Biol 2001;25:473-82.
10. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000;13:1134-42.
11. Miettinen M, El Rifai W, Sobin HL, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-83.
12. Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000;7:705-12.
13. Strickland L, Letson GD, Muro-Cacho CA. Gastrointestinal stromal tumors. Cancer Control 2001;8:252-61.
14. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3:655-64.
15. Demetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001;28:19-26.
16. Dematteo RP, Heinrich MC, El Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466-77.
17. Lehnen T. Gastrointestinal sarcoma (GIST)-a review of surgical management. Ann Chir Gynaecol 1998;87:297-305.
18. Bonvalot S, Boige V, Aparicio T, Lasser P, Elias D, Le Cesne A. Surgical management of gastrointestinal stromal tumors (GIST) (abstract). European Journal of Cancer 1999;35:1079.
19. Matthews BD, Walsh RM, Kercher KW, Sing RF, Pratt BL, Answini GA, et al. Laparoscopic vs open resection of gastric stromal tumors. Surg Endosc 2002;16:803-7.
20. Bouillot JL, Bresler L, Fagniez PL, Samama G, Champault G, Parent Y. Exérèse laparoscopique des tumeurs sous-muqueuses de l'estomac. À propos de 65 cas. Gastroenterol Clin Biol 2003;27:272-6.
21. Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003;54:3-24.
22. Yao KA, Talamonti MS, Langella RL, Schindler NM, Rao S, Small W, Jr., et al. Primary gastrointestinal sarcomas: analysis of prognostic factors and results of surgical management. Surgery 2000;128:604-12.
23. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992;215:68-77.
24. Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 1995;2:26-31.
25. Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
26. Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136:383-9.
27. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer 2000;88:66-74.
28. Ray-Coquard I, Le Cesne A, Michallet V, Boukovinas I, Ranchere D, Thiesse P, et al. Tumeurs stromales du tube digestif: actualités 2003. Bull Cancer 2003;90:69-76.
29. Dematteo RP, Shah A, Fong Y, Jarnagin WR, Blumgart LH, Brennan MF. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001;234:540-7.
30. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998;14:254-61.
31. Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey FJ, Eilber FR. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999;6:645-50.
32. Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey F, Eilber FR. Recurrent gastrointestinal stromal sarcomas. Surg Oncol 2000;9:71-5.
33. Calvacanti A, Bonvalot S, Elias D, Terrier P, Vanel D, Lepechoux C, et al. Intraperitoneal chemotherapy after complete resection of peritoneal sarcomatosis: results of a monocentric randomized study (abstract). European Journal of Cancer 2001;37:309.
34. Bauer TW, Hahn SM, Spitz FR, Kachur A, Glatstein E, Fraker DL. Preliminary report of photodynamic therapy for intraperitoneal sarcomatosis. Ann Surg Oncol 2001;8:254-9.
35. Hendren SK, Hahn SM, Spitz FR, Bauer TW, Rubin SC, Zhu T, et al. Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol 2001;8:65-71.
36. Cormier JN, Patel SR, Pisters PW. Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib. Curr Oncol Rep 2002;4:504-9.
37. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989;7:126-31.
38. Edmonson JH, Buckner JC, Long HJ, Loprinzi CL, Schaid DJ. Phase II study of ifosfamide-etoposide-mesna in adults with advanced non-osseous sarcomas. J Natl Cancer Inst 1989;81:863-6.
39. Loehrer PJ Sr, Sledge GW Jr, Nicaise C, Usakewicz J, Hainsworth JD, Martelo OJ, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol 1989;7:1655-9.
40. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Amman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208-16.
41. Plager C, Papadopoulos NE, Salem P. Adriamycin based chemotherapy for leiomyosarcoma of the stomach and small bowel (abstract). Proceeding of the American Society of Clinical Oncology 1991;10:352.
42. Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991;83:926-32.
43. Blair SC, Zalupski MM, Baker LH. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am J Clin Oncol 1994;17:480-4.
44. Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002;20:605-12.
45. Goss G, Merriam P, Manola J, Singer S, Fletcher C, Demetri G. Clinical and pathological characteristics of gastrointestinal stromal tumors (abstract). Proc ASCO 2000;19:2203.
46. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-9.
47. Ryan DP, Puchalski T, Supko JG, Harmon D, Maki R, Garcia-Carbonero R, et al. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 2002;7:531-8.
48. Plaat BE, Hollema H, Molenaar WM, Torn Broers GH, Pijpe J, Mastik MF, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18:3211-20.
49. Mavligit GM, Zukiwski AA, Salem PA, Lamki L, Wallace S. Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization. Cancer 1991;68:321-3.
50. Rajan DK, Soulen MC, Clark TW, Baum RA, Haskal ZJ, Shlansky-Goldberg RD, et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 2001;12:187-93.
51. Savage DG, Amman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-93.
52. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
53. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
54. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donate DP, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.
55. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
56. Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichard P, Blay JY, et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG (abstract). Proc Am Soc Clin Oncol 2003;22:3272.
57. Benjamin RS, Rankin C, Fletcher C, Blanke C, Von Mehren M, Maki R, et al. Phase III dose-randomized study of imatinib mesylate (Glivec, STI571) for GIST: Intergroup S0033 early results (abstract). Proc Am Soc Clin Oncol 2003;22:3271.
58. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donate DP, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38 Suppl 5:S83-S87.
59. Van den Abbeele AD, Badawi RD, Cliche JP. 18-FDG-PET predicts response to imatinib mesylate in patients with advanced gastrointestinal stromal tumors (abstract). Proc Am Soc Clin Oncol 2002;21:403.
60. Stroobants S, Goeminne J. Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20.
61. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Von Mehren M, et al. PDGFRA and KlT mutations correlate with the clinical responses to imatinib mesylate in patients with advanced gastrointestinal stromal tumors (abstract). Proc Am Soc Clin Oncol 2003;22:A3274.
62. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
63. Fletcher JA, Corless CL, Dimitrijevic S, Von Mehren M, Eisenberg B, Joensuu H, et al. Mechanisms of resistance to imatinib mesylate in advanced gastrointestinal stromal tumor (abstract). Proc Am Soc Clin Oncol 2003;22:A3275.
64. Van Glabbeke MM, Verweij J, Casali PG, J Zalcberg J, Le Cesne A, Reichard P, et al. Prognostic factors of toxicity and efficacy in patients with gastro-intestinal stromal tumors treated with imatinib: A study of the EORTC-STBSG, ISG and AGITG (abstract). Proc Am Soc Clin Oncol 2003;22:A3286.
65. Judson IR, Donate Di Paola E, Verweij J, Van Glabbeke MM, Ma P, et al. Population pharmacokinetic analysis and PK-pharmacodynamic correlations in Phase I/II trial of imatinib in gastrointestinal stromal tumours conducted by the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (abstract). Proc Am Soc Clin Oncol 2003;22:A3287.
66. Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM, et al. Association of KIT exon 9 mutations with non-gastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-37.
67. Demetri GD, George S, Heinrich MC, Fletcher JA, Fletcher CDM, Desai J, et al. Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor refractory to imatinib mesylate (abstract). Proc Am Soc Clin Oncol 2003;22:A3273.
68. Gunter E, Lingenfelser T, Eitelbach F, Muller H, Ell C. EUS-guided ethanol injection for treatment of a GI stromal tumor. Gastrointest Endosc 2003;57:113-5.